Investigational Drug for HER2 Tumors, Including Breast Cancer, Now Part of Alliance with Mersana, Takeda

Investigational Drug for HER2 Tumors, Including Breast Cancer, Now Part of Alliance with Mersana, Takeda
Takeda Pharmaceutical Company and Mersana Therapeutics have announced a new alliance that grants Takeda rights over XMT-1522, the lead product candidate of Mersana, outside the U.S. and Canada. The agreement also expands a previously existing collaboration between the two enterprises to allow Takeda access to Mersana’s antibody-drug conjugate (ADC) platform Fleximer, while granting Mersana an option at the end of Phase 1 to jointly develop and commercialize one of these programs in the U.S. Takeda and Mersana also will co-develop new payloads for use with ADCs. XMT-1522 is an investigational HER2-targeting therapy based on the Fleximer immunoconjugate technology. It carries nearly 15 proprietary auristatin payload molecules. The Fleximer-based ADC therapy targets HER2-expressing tumors, including gastric, breast cancer, and non-small cell lung cancers (NSCLC). Preclinical data shows that patients with HER2 low-expressing cancers reported significant anti-cancer activity, and patients with HER2 high-expressing cancers who had not responded well to currently available therapies also reported the same anti-tumor activity. “We believe XMT-1522 has the potential to make a dramatic difference for HER2 low-expressing patients who currently have limited treatment options, and are confident that our Fleximer-based technology can address significant patient needs not currently met by other ADC platform technologies,” Mersana President and CEO Anna Protopapas said in a press release. “Takeda’s knowledge of oncology and commitment to ADCs as a key therapeutic approach make the company the best partner for us to p
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.